Design Therapeutics Inc

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company that researches, designs, develops, and commercializes small molecule therapeutic drugs for genetic diseases in the United States. The company uses its GeneTAC platform to develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates target Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease. The company was incorporated in 2017 and is headquartered in Carlsbad, California.